Johnson & Johnson (NYSE:JNJ - Get Free Report) announced a quarterly dividend on Wednesday, July 16th, RTT News reports. Investors of record on Tuesday, August 26th will be paid a dividend of 1.30 per share on Tuesday, September 9th. This represents a $5.20 dividend on an annualized basis and a yield of 3.19%.
Johnson & Johnson has a dividend payout ratio of 46.8% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Johnson & Johnson to earn $11.07 per share next year, which means the company should continue to be able to cover its $5.20 annual dividend with an expected future payout ratio of 47.0%.
Johnson & Johnson Stock Performance
Shares of JNJ traded down $1.62 during trading hours on Thursday, hitting $163.16. The company's stock had a trading volume of 7,469,134 shares, compared to its average volume of 8,149,524. The company has a market cap of $392.57 billion, a price-to-earnings ratio of 18.15, a PEG ratio of 2.12 and a beta of 0.41. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. The business has a 50 day simple moving average of $153.95 and a two-hundred day simple moving average of $154.71. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The business's revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.82 EPS. On average, equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.
Analysts Set New Price Targets
JNJ has been the subject of a number of research reports. UBS Group reissued a "buy" rating and issued a $190.00 price target (up previously from $180.00) on shares of Johnson & Johnson in a research note on Thursday. Raymond James Financial reduced their target price on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research note on Monday, April 14th. Piper Sandler reaffirmed an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday. The Goldman Sachs Group upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their price objective for the company from $157.00 to $172.00 in a research report on Wednesday, April 9th. Finally, Morgan Stanley upped their target price on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday. Eleven research analysts have rated the stock with a hold rating, nine have assigned a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus price target of $174.11.
Check Out Our Latest Research Report on JNJ
Institutional Trading of Johnson & Johnson
An institutional investor recently raised its position in Johnson & Johnson stock. Brighton Jones LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 13.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 51,876 shares of the company's stock after purchasing an additional 6,332 shares during the period. Brighton Jones LLC's holdings in Johnson & Johnson were worth $7,502,000 at the end of the most recent reporting period. 69.55% of the stock is currently owned by institutional investors and hedge funds.
About Johnson & Johnson
(
Get Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Recommended Stories
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
